Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Trial results in Covid-19 and cancer emerge, but little promise is seen.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.